Literature DB >> 23373633

Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

S Sengupta1, I Obiorah, P Y Maximov, R Curpan, V C Jordan.   

Abstract

BACKGROUND AND
PURPOSE: Oestrogen receptor alpha (ERα) binds to different ligand which can function as complete/partial oestrogen-agonist or antagonist. This depends on the chemical structure of the ligands which modulates the transcriptional activity of the oestrogen-responsive genes by altering the conformation of the liganded-ERα complex. This study determined the molecular mechanism of oestrogen-agonistic/antagonistic action of structurally similar ligands, bisphenol (BP) and bisphenol A (BPA) on cell proliferation and apoptosis of ERα + ve breast cancer cells. EXPERIMENTAL APPROACH: DNA was measured to assess the proliferation and apoptosis of breast cancer cells. RT-PCR and ChIP assays were performed to quantify the transcripts of TFF1 gene and recruitment of ERα and SRC3 at the promoter of TFF1 gene respectively. Molecular docking was used to delineate the binding modes of BP and BPA with the ERα. PCR-based arrays were used to study the regulation of the apoptotic genes. KEY
RESULTS: BP and BPA induced the proliferation of breast cancer cells; however, unlike BPA, BP failed to induce apoptosis. BPA consistently acted as an agonist in our studies but BP exhibited mixed agonistic/antagonistic properties. Molecular docking revealed agonistic and antagonistic mode of binding for BPA and BP respectively. BPA treatment resembled E2 treatment in terms of PCR-based regulation of apoptotic genes whereas BP was similar to 4OHT treatment. CONCLUSIONS AND IMPLICATIONS: The chemical structure of ERα ligand determines the agonistic or antagonistic biological responses by the virtue of their binding mode, conformation of the liganded-ERα complex and the context of the cellular function.
© 2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23373633      PMCID: PMC3632247          DOI: 10.1111/bph.12122

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.

Authors:  Joan S Lewis; Kathleen Meeke; Clodia Osipo; Eric A Ross; Noman Kidawi; Tianyu Li; Eric Bell; Navdeep S Chandel; V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2005-12-07       Impact factor: 13.506

2.  Molecular classification of estrogens.

Authors:  V C Jordan; J M Schafer; A S Levenson; H Liu; K M Pease; L A Simons; J W Zapf
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

3.  Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo.

Authors:  Xue-Feng Liu; Milan K Bagchi
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

4.  Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells.

Authors:  Sandrine Bourgoin-Voillard; Dominique Gallo; Ioanna Laïos; Anny Cleeren; Latifa El Bali; Yves Jacquot; Denis Nonclercq; Guy Laurent; Jean-Claude Tabet; Guy Leclercq
Journal:  Biochem Pharmacol       Date:  2009-10-29       Impact factor: 5.858

5.  Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.

Authors:  V C Jordan; M E Lieberman
Journal:  Mol Pharmacol       Date:  1984-09       Impact factor: 4.436

6.  Coactivator AIB1 links estrogen receptor transcriptional activity and stability.

Authors:  Wenlin Shao; Erika Krasnickas Keeton; Donald P McDonnell; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

7.  Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol.

Authors:  J C Gould; L S Leonard; S C Maness; B L Wagner; K Conner; T Zacharewski; S Safe; D P McDonnell; K W Gaido
Journal:  Mol Cell Endocrinol       Date:  1998-07-25       Impact factor: 4.102

8.  An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

Authors:  S Y Jiang; D M Wolf; J M Yingling; C Chang; V C Jordan
Journal:  Mol Cell Endocrinol       Date:  1992-12       Impact factor: 4.102

9.  Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens.

Authors:  David Bentrem; Jennifer E Fox; Sandra Timm Pearce; Hong Liu; Sam Pappas; David Kupfer; James W Zapf; V Craig Jordan
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

10.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

View more
  39 in total

1.  Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.

Authors:  Surojeet Sengupta; Michael C Biarnes; Robert Clarke; V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2015-02-27       Impact factor: 4.872

2.  Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

3.  Avoiding the bad and enhancing the good of soy supplements in breast cancer.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-04       Impact factor: 13.506

4.  Co-treatment of mouse antral follicles with 17β-estradiol interferes with mono-2-ethylhexyl phthalate (MEHP)-induced atresia and altered apoptosis gene expression.

Authors:  Zelieann R Craig; Jeffrey Singh; Rupesh K Gupta; Jodi A Flaws
Journal:  Reprod Toxicol       Date:  2014-01-09       Impact factor: 3.143

5.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

6.  Bisphenol A Induces Sox2 in ER+ Breast Cancer Stem-Like Cells.

Authors:  M Angeles Lillo; Cydney Nichols; Tiffany N Seagroves; Gustavo A Miranda-Carboni; Susan A Krum
Journal:  Horm Cancer       Date:  2017-02-27       Impact factor: 3.869

Review 7.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

8.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

10.  Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo.

Authors:  Paromita Deb; Arunoday Bhan; Imran Hussain; Khairul I Ansari; Samara A Bobzean; Tej K Pandita; Linda I Perrotti; Subhrangsu S Mandal
Journal:  Gene       Date:  2016-05-13       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.